OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them.
For the last 25 years, Dr. Prato and his team have helped thousands of patients that have failed the largest hospitals utilizing the techniques and technology discussed in this series. Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on: DNA, RNA, and immune-based targeting, the truth behind standard protocols, what most doctors miss in treatment planning, stories of hope from patients who’ve been told “there’s nothing more we can do”
We believe in personalized, data-driven medicine — not protocol-based guessing.
You don’t have to fight cancer blindly. You can OutSmart it.
Disclaimer: This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico.
OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
Blood Cancer Recurrence Isn't Treatment Failure—It's This
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
This video explains why blood cancer can recur, often due to minimal residual disease (MRD) that goes undetected despite initial treatment success.
We discuss how initial improvements in scans and blood counts can be misleading, as unseen disease may persist and lead to relapse. Understanding this is crucial for effective blood cancer treatment and preventing future challenges.
🎯 What You’ll Learn in This Episode:
- What minimal residual disease really is
- Why remission alone isn’t enough in blood cancers
- How MRD causes relapse months or years later
- The difference between transplant vs short-term immune strike
- How borrowed donor immune cells can target MRD
- Why timing matters (not for active blast crisis)
- How MRD can be tested and monitored
- The questions to ask your doctor after remission
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576
“Relapse doesn’t start big — it starts with what was left behind.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493